Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05433142 · ClinicalTrials.gov registry record · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
A Phase 1 study of Clear Cell Renal Cell Carcinoma, sponsored by Xencor.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 307
- Enrollment target
- 20
- Study locations
NCT05433142 is a Phase 1 study of Clear Cell Renal Cell Carcinoma that is actively recruiting participants, run by Xencor. The registered enrollment target is 307 participants, above the 196-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (57% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT05433142, a Phase 1 study of Clear Cell Renal Cell Carcinoma, is actively recruiting participants, sponsored by Xencor.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 307 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Conditions Studied
Interventions
- BIOLOGICAL XmAb819
Study Locations (20)
California
- Xencor Investigative Site - Duarte
- Xencor Investigative Site - Sacramento
Illinois
- Xencor Investigative Site - Chicago
- Xencor Investigative Site - Chicago
New York
- Xencor Investigative Site - New York
- Xencor Investigative Site - New York
North Carolina
- Xencor Investigative Site - Charlotte
- Xencor Investigative Site - Durham
Ohio
- Xencor Investigative Site - Cincinnati
- Xencor Investigative Site - Columbus
Arizona
- Xencor Investigative Site - Phoenix
Connecticut
- Xencor Investigative Site - New Haven
Florida
- Xencor Investigative Site - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2022-06-13 |
| Est. Completion | 2028-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05433142
The ClinicalTrials.gov registry entry for NCT05433142 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 307 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 196-participant average among 45 other Clear Cell Renal Cell Carcinoma trials with a reported enrollment target (57% higher). The listed sponsor is Xencor, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clear Cell Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which XmAb819 is the first listed.
NCT05433142 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT05433142 about?
NCT05433142 is a clinical study titled "Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma". The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
What is the current status of trial NCT05433142?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 307 participants. The study started on 2022-06-13. Estimated completion is 2028-12.
What conditions does trial NCT05433142 study?
This clinical trial studies the following conditions: Clear Cell Renal Cell Carcinoma.
What interventions are being tested in trial NCT05433142?
The interventions under investigation include: XmAb819 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05433142?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05433142 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clear Cell Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Beta-only IL-2 ImmunoTherapY Study
RECRUITING · Phase 1
-
A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RECRUITING · Phase 1
-
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
-
[18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.